Most Recent
Bayer has lost its battle to protect top-selling blood thinner Xarelto from generic competition, with the Full Court finding two patents for the drug are invalid.
Novartis unit Sandoz AG has filed an appeal after it was was barred from selling a generic version of top-selling blood clot drug Xarelto and failed to revoke two Bayer patents for the drug.
Novartis unit Sandoz AG has lost its bid to revoke Bayer’s patents for its top-selling blood clot drug Xarelto and has been barred from selling generic versions of the medication after a judge found the German pharma giant’s patents were valid.
CSIRO has won its bid to access samples of a wheat grain product with increased fibre, as it contemplates a possible patent infringement lawsuit against a South Australian food company.
German pharmaceutical giant Bayer has slammed generic drug make Sandoz’s late bid for documents, which it called an attempt to “divert and distract” Bayer on the eve of a three-week trial over the patents for its top-selling blood clot drug Xarelto.
Global pharmaceutical giant Pfizer has successfully defended the patent for its sedative drug Precedex against a validity challenge, a big win for the drug maker after a US court found last year that its patents for a ready-to-use version of the drug were invalid for obviousness.